Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 26, 2026

Back to today

Merger Monday & Election Implications

EQT’s $50 billion merger with Range Resources and Ovintiv’s $1.26 billion acquisition of Logan Energy reshape North American oil and gas alongside Brazil and British Columbia election…

EQT $34BRRC $11B
Bison Insights 7 clicks

From X

@convequity 1 click

Convequity on X

The neocloud debt pullback is about how long delivery takes, and the useful response is a targeted renegotiation that pays lenders for more time, not a liquidation of the borrowers. Demand for AI compute is huge, and investors were eager to fund the buildout. That demand is still there. What is drying up is debt for neoclouds that cannot show revenue outside AI data centers. In our view the pullback is almost entirely about timing. Compute gets billed only once the site is built, powered and staffed, long after the cash has gone in. That wait is the squeeze. As a hypothetical, if the neoclouds could stand compute up and start billing ten times faster, the problem would ease. They would be generating revenue and cash flow to fund more of the next investment themselves, and outside investors could ask less interest on future money. On the latest reported figures, $CRWV's operating cash flow is positive but its free cash flow is negative, because the build is still being paid for. Lenders are now pulling back from neoclouds that have no revenue outside AI data centers. The race between neoclouds pushed CoreWeave too far. They took the debt probably knowing the delivery timetable was tight, because a firm that is not aggressive enough ends up with no compute at all. If lenders call a default and CoreWeave is then bankrupted and liquidated, the credit investors are left holding the GPUs. Taking the collateral does not make it earn. Someone still has to power, staff and bill the site, so the lenders must find another company to run it. In our view they lose money net-net, the handover is costly, and the buildout stalls to a degree. Amazon, Microsoft and Google can keep funding GPUs from businesses that already earn. A stall on the independent side leaves more AI compute with them, which in our view is bad for an AI-led economy. Who would buy a failed neocloud is still open. Blanket leniency would be a moral-hazard problem. If every late project gets time for free, covenants stop binding and the next borrower takes the same risk again. The exception here is that the demand behind the loans is still there. A lender can give more time to a project that will cover its debt once it is billing, and be paid for the wait with a higher margin, a fee or upside. When the cash flow recovers, that is the lender's reward. Musk predicting that 200-plus neoclouds will fail or consolidate makes the pullback worse. More credit investors step back, and the wait gets longer for everyone still building.
@kevin__mak 6 clicks

Kevin Mak on X

$CMPS Great article this weekend in Politico about psychedelics. There's overwhelming alignment across the government to moving these treatments forward. Given this, I really can't see COMP360 getting ensnared in the approval process, or worse, through reimbursement/REMS bureaucracy once commercialized. At current prices, I believe the market is treating CMPS as a "risky proposition" because historically, that was very true. I think that regime has changed dramatically in the last 12 months. Spend some time talking to an LLM about COMP360 vs Spravato (>$2B/year in sales). Which would you rather take? But even more importantly, Spravato has <5% market share of Treatment Resistant Depression, the other ~95% of patients are generally seeking options. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. --- The VA has led the push in Washington to advance access to psychedelic therapy. It’s involved in 20 psychedelic clinical trials and was one of the first major health care systems to roll out Spravato, an FDA-approved treatment for depression using esketamine, a chemical component found in ketamine. Ketamine — an anesthetic frequently referred to as a psychedelic due to its psychoactive effects — is currently the only psychedelic-like drug approved for medical use. Trump administration officials say they hope more will be approved soon. “We want to see the drug approved if it’s safe and effective, and the reason why is because there’s a mental health crisis,” Matt Zorn, deputy general counsel at the Health and Human Services Department, told POLITICO.

Investor Letters

All letters

Molina & Kinsale

Molina Healthcare and Kinsale Capital’s earnings are reassessed through a long-term lens, emphasizing conviction and detachment during…

MOH $11BKNSL $8.6B
Bearstone 6 clicks
WRBY · long

Warby Parker

Warby Parker's $25 valuation does not capture potential upside from smartglasses alongside its core omnichannel eyewear business.

WRBY $3.2B
Value Investors Club 3 clicks

Tower Semiconductor Deep Dive

Tower Semiconductor’s low-loss photonics chips halve lasers in 1.6T optical modules, supporting a $680 million annualized photonics run…

TSEM $19B
CV's Substack 9 clicks

Margin Call

Petrobras’s Morpho-1 well revived hopes that Brazil’s Equatorial Margin can become a major new oil frontier after hydrocarbons were…

PBR $83B
Doomberg 9 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 254

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.